EGFR-targeted CAR-T cell therapy has been applied in clinical trials to treat various cancers, including triple-negative breast cancer, head and neck cancer, glioblastoma, and non-small cell lung cancer, and some of them have shown promising outcomes [9,10,11,12]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.